Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma

Journal of Microbiology and Biotechnology

Volumn 18, Issue 5, 2008, Pages 997-1003

  Kim, In Seop ^a   Choi, Yong Woon ^b,c   Kang, Yong ^b   Sung, Hark Mo ^a,b   Shin, Jeong Sup ^b,c  

^a Hannam University   (South Korea)

^b Green Cross Company   (South Korea)

^c Ajou University   (South Korea)

Author keywords

Antihemophilic factor VIII; Dry heat treatment; Hepatitis A virus; Virus inactivation

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; DETERGENT; SOLVENT;

ANIMAL EXPERIMENT; ARTICLE; BOVINE DIARRHEA VIRUS; BOVINE HERPES VIRUS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MANUFACTURE; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; FREEZE DRYING; HEPATITIS A VIRUS; HIGH TEMPERATURE PROCEDURES; HUMAN IMMUNODEFICIENCY VIRUS; HYPERTHERMIC THERAPY; MOUSE; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; PORCINE PARVOVIRUS; VIRUS INACTIVATION; VIRUS RESISTANCE;

ANIMALS; CATTLE; CELL LINE; CERCOPITHECUS AETHIOPS; DRUG CONTAMINATION; DRUG INDUSTRY; DRUG STABILITY; FACTOR VIII; FREEZE DRYING; HEAT; HUMANS; PLASMA; SWINE; VERO CELLS; VIRUS CULTIVATION; VIRUS INACTIVATION; VIRUSES;

BOVINAE; BOVINE VIRAL DIARRHEA VIRUS 1; ENCEPHALOMYOCARDITIS VIRUS; HEPATITIS A VIRUS; HERPESVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS; MURINAE; PORCINE PARVOVIRUS;

EID: 50249090340     PISSN: 10177825     EISSN: 17388872     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Addiego, Jr. J. E., E. Gomperts, S. Liu, P. Bailey, S. G. Courter, M. L. Lee, G. G. Neslund, H. S. Kingdom and M. J. Griffith. 1992. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc inimunoaffinity chromatography. Thromb. Haemost. 67: 19-27.
2. Andrewes, C. 1989. Andrewes' Viruses of Vertebrates, pp. 120-145. Balliere Tindal, London, U.K.
3. Berkman, S. A. 1988. Infectious complications of blood transfusion. Blood Rev. 2: 206-210.
4. Boschetti, N., I. Niederhauser, C. Kempf, A. Stuhler, J. Lower, and J. Blumel. 2004. Different susceptibility of B19 virus and mice minute virus to low pH treatment. Transfusion 44: 1079-1086.
5. Burnouf, T. and M. Radosevich. 2000. Reducing the risk of infection from plasma products: Specific preventative strategies. Blood Rev. 14: 94-110.
6. Carpenter, J. F., M. J. Pikal, B. S. Chang, and T. W. Randolph. 1997. Rational design of stable lyophilized protein formulations: Some practical advice. Pharm. Res. 14: 969-975.
7. Chudy, M., I. Budek, B. Keller-Stanislawski, K. A. McCaustland, S. Neidhold, B. H. Robertson, C. M. Nubling, R. Seitz, and J. Lower. 1999. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J. Med. Virol. 57: 91-99.
8. Dichtelmuller, H., D. Rudnick, B. Breuer, R. Kotitschke, M. Kloft, A. Darling, et al. 1996. Improvement of virus safety of a S/D treated factor VIII concentrate by additional dry heat treatment at 100°C. Biologicals 24: 125-130.
9. Gummadi, S. N. 2003. What is the role of thermodynamics on protein stability? Biotechnol. Bioprocess Eng. 8: 9-18.
10. Hoyer, L. W. 1994. Hemophilia A. N. Engl. J. Med. 330: 38.
11. International Conference on Harmonisation. 1998. Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability. Federal Register 63: 51074-51084.
12. Jee, Y. M., U. Go, D. Cheon, Y. Kang, J. D. Yoon, S. W. Lee, et al. 2006. Detection of hepatitis A virus from clotting factors implicated as a source of HAV infection among haemophilia patients in Korea. Epidemiol. Infect. 134: 87-93.
13. Kärber, J. 1931. Beitrag zur kollectiven Behandlung pharmakologische Reihenversuche. Arch. Exp. Path. Pharmak. 162: 480-483.
14. Kim, H., Y. Jee, H-S. Mun, B.-C. Song, J.-H. Park, J.-W. Hyun, et al. 2007. Comparison of full genome sequences between two hepatitis B virus strains with or without preC mutation (A1896) from a single Korean hepatocellular carcinoma patient. J. Microbiol. Biotechnol. 17: 701-704.
15. Kim, I. S. 2003. Comparative inactivation of hepatitis A virus and murine encephalomyocarditis virus to various inactivation processes. Kor. J. Microbiol. 39: 242-247.
16. Kim, I. S., H. G. Eo, C. W. Park, C. E. Chang, and S. Lee. 2001. Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and pasteurization during the manufacture of albumin and immunoglobulins from human plasma. Biotechnol. Bioprocess Eng. 6: 25-30.
17. Kim, I. S., Y. W. Choi, and S. R. Lee. 2004. Optimization and validation of a virus filtration process for efficient removal of viruses from urokinase solution prepared from human urine. J. Microbiol. Biotechnol. 14: 140-147.
18. Kim, I. S., Y. W. Choi, S. R. Lee, and H. M. Sung. 2004. Cold ethanol fractionation and heat inactivation of hepatitis A virus during manufacture of albumin from human plasma. Biotechnol. Bioprocess Eng. 9: 57-60.
19. Kim, I.S., Y. W. Choi, S. R. Lee, H. S. Woo, and S. Lee. 2001. Removal and inactivation of viruses during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. Biotechnol. 11: 497-503.
20. Kim, I. S., Y. W. Choi, S. R. Lee, M. S. Lee, K. H. Huh, and S. Lee. 2001. Removal and inactivation of hepatitis A virus during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. 39: 67-73.
21. Kim, I. S., Y. W. Choi, S. R. Lee, Y. Kang, K. M. Lee, D. H. Park, H. S. Woo, and S. Lee. 2002. Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine. Biotechnol. Bioprocess Eng. 7: 340-346.
22. Klein, H. G. 2005. Pathogen inactivation technology: Cleansing the blood supply. J. Intern. Med. 257: 224-237.
23. Lauh, R. and P. Strengers. 2002. Parvovirus and blood products. Pathol. Biol. (Paris) 50: 339-348.
24. Lemon, S. M. 1994. The natural history of hepatitis A: The potential for transmission by transfusion of blood or blood products. Vox Sang. 67(Suppl 4): 19-23.
25. Morgenthaler, J. J. 2000. New development in plasma fractionation and virus inactivation. Vox Sang 78(Suppl 2): 217-221.
26. Mosley, J. W. and J. Rakela. 1999. Foundling viruses and transfusion medicine. Transfusion 39: 1041-1044.
27. Murgatroyd, K. 1997. The freeze drying process, pp. 1-58. In P. Cameron (ed.), Good Pharmaceutical Freeze-Drying Practice. Interpharm Press, IL, U.S.A.
28. Powell J. S., M. Bush, J. Harrison, C. Abildgaard, E. Vosburgh, A. R. Thompson, and D. Hurst. 2000. Safety and efficacy of solvent/ detergent-treated antihaemophilic factor with an added 80°C terminal dry heat treatment in patients with haemophilia A. Haemophilia 6: 140-149.
29. Roberts, P. L. and H. Hart. 2000. Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates. Biologicals 28: 185-188.
30. Robertson, B. H. and D. D. Erdman. 2000. Non-enveloped viruses transmitted by blood and blood products. Dev. Biol. Stand. 102: 29-35.
31. Robinson, S. M., H. Schwinn, and A. Smith. 1992. Clotting factors and hepatitis A. Lancet 340: 1465.
32. Shin, J. S., Y. W. Choi, H. M. Sung, Y.-W. Ryu, and I. S. Kim. 2006. Enhanced virus safety of a solvent/detergent-treated antihemophilic factor IX concentrate by dry-heat treatment. Biotechnol. Bioprocess Eng. 11: 19-25.
33. Shin, K-S., J. H. Lim, J.-H. Kim, H. Myung, and S.-W. Lee. 2006. Inhibition of the replication of hepatitis C virus replicon with nuclease-resistant RNA aptamers. J. Microbiol. Biotechnol. 16: 1634-1639.
34. Song, M.-S., Y. Joo, E. H. Lee, J.-Y. Shin, C.-J. Kim, K-S. Shin, M. H. Sung, and Y. K. Choi. 2006. Genetic characterization of encephalomyocarditis virus isolated from aborted swine fetus in Korea. J. Microbiol. Biotechnol. 16: 1570-1576.
35. Tabor, E. 1999. The epidemiology of virus transmission by plasma derivatives: Clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 39: 1160-1168.